Single-cell analysis has great promise… but how can we get there? by Zachary Pitluk
Single-cell analysis has great promise… but how can we get there? by Zachary Pitluk
25th October 2022: Paradigm4’s REVEAL Integrative Analytics platform enables Alnylam Pharmaceuticals to discover novel, genetically-validated drug targets from population scale biobank genotype-phenotype datasets and underlies the extraordinary pace and productivity of Alnylam’s RNAi therapeutics pipeline. Using Paradigm4’s cloud-based scientific analytics platform and data from the UK Biobank, Alnylam has identified
Dr. Zach Pitluk and Dr. Srikant Sarangi on preparing the way for AI/ML to impact drug discovery and development.
The recent Human Cell Atlas (HCA) 2022 General Meeting, hosted in Vienna, Austria, provided a great opportunity for me to catch up on progress towards the HCA’s goal of mapping every cell type in the human body. I also got the chance to hear presentations that either highlighted new insights